A selective RARβ2 agonist mitigates HSC activation and early fibrosis events in HFD-induced NAFLD mouse models [90,94], while RARγ activation has no effect [94]. The gene discussed is RARG; the disease is metabolic dysfunction-associated steatotic liver disease.